Passenger Lymphocyte Syndrome and Liver Transplantation
Author Information
Author(s): Maxime Audet, Fabrizio Panaro, Tullio Piardi, Ping Huang, Murat Cinqualbre, Jacques Wolf, Philippe Cag
Primary Institution: Centre de Chirurgie Viscérale et de Transplantation, Hôpital de Hautepierre, Hopitaux Universitaires de Strasbourg-Université Louis Pasteur
Conclusion
Passenger lymphocyte syndrome (PLS) is a common complication in liver transplantation, occurring in 30%–40% of recipients, and can be managed with transfusions and immunosuppressive therapies.
Supporting Evidence
- PLS can develop in 30%–40% of liver transplant recipients.
- The antibodies involved in PLS are often directed against Rh blood group antigens.
- Management strategies for PLS include transfusions and immunosuppression.
Takeaway
Sometimes when people get new organs, their body can react badly because of the donor's cells. This can cause problems like anemia, but doctors have ways to help fix it.
Methodology
The authors reviewed literature about passenger lymphocyte syndrome (PLS) in liver transplantation, discussing its definition, mechanisms, clinical features, and treatment options.
Limitations
The study is based on literature review and lacks large-scale data or specific predictive factors for PLS development.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website